Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.

Moosmann B, Behl C.

Trends Cardiovasc Med. 2004 Oct;14(7):273-81. Review.

PMID:
15542379
2.

Selenoprotein synthesis and side-effects of statins.

Moosmann B, Behl C.

Lancet. 2004 Mar 13;363(9412):892-4. Review.

PMID:
15031036
3.

Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine.

Warner GJ, Berry MJ, Moustafa ME, Carlson BA, Hatfield DL, Faust JR.

J Biol Chem. 2000 Sep 8;275(36):28110-9.

4.

Mammalian Trit1 is a tRNA([Ser]Sec)-isopentenyl transferase required for full selenoprotein expression.

Fradejas N, Carlson BA, Rijntjes E, Becker NP, Tobe R, Schweizer U.

Biochem J. 2013 Mar 1;450(2):427-32. doi: 10.1042/BJ20121713.

PMID:
23289710
5.

Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways.

Kromer A, Moosmann B.

Mol Pharmacol. 2009 Jun;75(6):1421-9. doi: 10.1124/mol.108.053678. Epub 2009 Mar 30.

6.

Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.

Paumelle R, Staels B.

Trends Cardiovasc Med. 2008 Apr;18(3):73-8. doi: 10.1016/j.tcm.2008.01.001. Review.

PMID:
18436144
7.

Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.

Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, Huff MW.

J Biol Chem. 2005 Jun 10;280(23):22212-21. Epub 2005 Apr 6.

8.

The canonical pathway for selenocysteine insertion is dispensable in Trypanosomes.

Aeby E, Palioura S, Pusnik M, Marazzi J, Lieberman A, Ullu E, Söll D, Schneider A.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5088-92. doi: 10.1073/pnas.0901575106. Epub 2009 Mar 11.

9.

Growth inhibition of Candida species and Aspergillus fumigatus by statins.

Macreadie IG, Johnson G, Schlosser T, Macreadie PI.

FEMS Microbiol Lett. 2006 Sep;262(1):9-13.

10.

HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.

Kandoussi A, Martin F, Hazzan M, Noël C, Fruchart JC, Staels B, Duriez P.

Clin Sci (Lond). 2002 Aug;103 Suppl 48:81S-83S.

PMID:
12193060
11.

Pleiotropic effects of statins and related pharmacological experimental approaches.

Alegret M, Silvestre JS.

Methods Find Exp Clin Pharmacol. 2006 Nov;28(9):627-56. Review.

PMID:
17200729
12.

HMG-CoA reductase inhibitors and coenzyme Q10.

Nawarskas JJ.

Cardiol Rev. 2005 Mar-Apr;13(2):76-9. Review.

PMID:
15705257
13.

New lipid-lowering agents acting on LDL receptors.

Scharnagl H, März W.

Curr Top Med Chem. 2005;5(3):233-42. Review.

PMID:
15857307
14.

Anti-cancer therapy: targeting the mevalonate pathway.

Swanson KM, Hohl RJ.

Curr Cancer Drug Targets. 2006 Feb;6(1):15-37. Review.

PMID:
16475974
15.

Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.

Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS.

J Cardiovasc Pharmacol. 2005 Sep;46(3):377-86.

PMID:
16116345
16.

Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.

Arnaud C, Veillard NR, Mach F.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):127-34. Review.

PMID:
15853754
17.

Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.

Kumai T, Matsumoto N, Koitabashi Y, Takeba Y, Oonuma S, Sekine S, Tadokoro M, Kobayashi S.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul;3(3):195-201. Review.

PMID:
15974884
18.

Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function.

Carlson BA, Novoselov SV, Kumaraswamy E, Lee BJ, Anver MR, Gladyshev VN, Hatfield DL.

J Biol Chem. 2004 Feb 27;279(9):8011-7. Epub 2003 Dec 4.

19.

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

Dimitroulakos J, Lorimer IA, Goss G.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4426s-4431s. Review.

20.

Statins and cancer development.

Duncan RE, El-Sohemy A, Archer MC.

Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1897-8. Review.

Supplemental Content

Support Center